L7 STR



REP G1=(0-2) C
VAR G2=7/9/10
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8 13
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

=> s l7 ful
FULL SEARCH INITIATED 12:08:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 40161 TO ITERATE

100.0% PROCESSED 40161 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.02

L9 25 SEA SSS FUL L7

=> d scan

L9 25 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-Benzimidazol-2-one, 1-[1-[[4-[3-amino-1-[2-(4-morpholinyl)ethyl]-5-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-
MF C37 H40 N8 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	185.26	185.47

FILE 'CAPLUS' ENTERED AT 12:08:21 ON 07 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Jul 2008 VOL 149 ISS 2
FILE LAST UPDATED: 6 Jul 2008 (20080706/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l9
L10 2 L9

=> d bib abs 1-2

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:338631 CAPLUS
DN 148:528852
TI Rapid assembly of diverse and potent allosteric Akt inhibitors

AU Wu, Zhicai; Robinson, Ronald G.; Fu, Sheng; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Kral, Astrid M.; Huber, Hans E.; Kohl, Nancy E.; Hartman, George D.; Bilodeau, Mark T.

CS Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., West Point, PA, 19486, USA

SO Bioorganic & Medicinal Chemistry Letters (2008), 18(6), 2211-2214 CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Ltd.

DT Journal

LA English

AB This paper describes the rapid assembly of four different classes of potent Akt inhibitors from a common intermediate. Among them, a pyridopyrimidine series displayed the best intrinsic and cell potency against Akt1 and Akt2. This series also showed a promising pharmacokinetic profile and excellent selectivity over other closely related kinases.

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:964996 CAPLUS

DN 141:406037

TI Heterocyclic compound inhibitors of Akt kinase activity, and use for the treatment of cancer

IN Bilodeau, Mark T.; Wu, Zhicai

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 62 pp. CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096130	A2	20041111	WO 2004-US12187	20040420
	WO 2004096130	A3	20050407		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004233827	A1	20041111	AU 2004-233827	20040420
	CA 2522430	A1	20041111	CA 2004-2522430	20040420
	EP 1620095	A2	20060201	EP 2004-760293	20040420
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1809351	A	20060726	CN 2004-80017101	20040420
	JP 2006524254	T	20061026	JP 2006-513159	20040420
	US 20060205765	A1	20060914	US 2005-554185	20051021
PRAI	US 2003-465123P	P	20030424		
	WO 2004-US12187	W	20040420		

OS MARPAT 141:406037

GI



I

AB The invention discloses compds. which contain a five-membered heterocyclic ring fused to a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention further discloses chemotherapeutic compns. containing the compds. of the invention and methods for treating cancer comprising administration of the compds. of the invention. Preparation of compds., e.g. I, is described.